DUSA Pharmaceuticals Reports Third Quarter 2009 Corporate Highlights and
Financial Results
Q3 Domestic PDT revenues up 32% year over year; Q3 Non-GAAP loss improves 86%
year over year to ($0.2) million
WILMINGTON, Mass., Nov. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals,
Inc.® (Nasdaq GM: DUSA), a dermatology company that is developing and
marketing Levulan® Photodynamic Therapy (PDT) and other products focused on
patients with common skin conditions, reported today its corporate highlights
and financial results for the third quarter ended September 30, 2009.
Third quarter and year-to-date financial highlights include:
-- Domestic PDT revenues totaled $6.2 million for the third quarter of
2009, representing a $1.5 million, or 32%, improvement as compared to
the third quarter of 2008. Year-to-date 2009 domestic PDT revenues
totaled $18.7 million, representing a $3.8 million, or 25%,
improvement
year over year.
-- Domestic Kerastick® revenues totaled $5.8 million for the third
quarter
of 2009, representing a $1.4 million, or 32%, improvement as compared
to
the third quarter of 2008. Year-to-date 2009 domestic Kerastick®
revenues totaled $17.1 million, representing a $3.4 million, or 25%,
improvement year over year.
-- Domestic BLU-U® revenues totaled $0.5 million for the third quarter of
2009, representing a $0.1 million, or 22%, improvement as compared to
the third quarter of 2008. Year-to-date 2009 domestic BLU-U® revenues
totaled $1.6 million, representing a $0.4 million, or 32%, improvement
year over year.
-- Kerastick® gross margins for the third quarter of 2009 reached a
record
high of 86%.
-- Non-GAAP loss for the third quarter of 2009 improved 86% year over
year,
and narrowed to $0.2 million.
Management Comments:
"We are excited to report the improvement in many of our key financial
indicators this quarter," stated Robert Doman, President and CEO. "The
combination of strong top line PDT revenue growth, the achievement of record
Kerastick margins, and reductions in our overall spending drove our non-GAAP
loss to a record low point."
"We experienced significant growth in Kerastick revenue during the third
quarter. This is due in part to solid execution by the sales and marketing
team and a 33% increase in BLU-U volume year-to-date. This represents the
16th consecutive quarter of year over year domestic Kerastick growth."
"In October, we announced an important milestone in the Company's history,
having surpassed cumulative Kerastick sales of one million units. The
achievement of this milestone demonstrates the relevance that PDT is gaining
in the medical dermatology community," continued Doman.
"For the remainder of the year, we will focus our efforts on further
capitalizing on the significant growth potential that exists for Levulan PDT
in the treatment of actinic keratoses (AKs)," concluded Doman.
Third Quarter 2009 Financial Results:
Total product revenues were $6.9 million in the third quarter of 2009, up 21%
from $5.7 million in the third quarter of 2008. PDT revenues totaled $6.7
million, up $1.5 million, or 30%, from $5.2 million for the comparable 2008
period. The increase in PDT revenues was attributable to a 32% increase in
Kerastick® revenues and a 7% increase in BLU-U® revenues. The Kerastick®
revenue improvement was driven by a 20% increase in our domestic Kerastick®
volume and an overall 10% increase in our average selling price. Kerastick®
sales volumes increased to 53,622 in the third quarter of 2009 from 44,668
units sold in the third quarter of 2008. Domestic Kerastick® sales volumes
increased by 7,938 units, or 20%, and were supplemented by a 1,016 unit
increase in our international sales volumes. The BLU-U® revenue increase was
driven by a 4% increase in sales volume. There were 59 units sold during the
quarter, as compared to the prior year quarterly total of 57 units. Non-PDT
revenues totaled $0.2 million versus $0.6 million for the comparable 2008
period. Non-PDT revenues were adversely impacted by the absence of Nicomide®
royalty revenues in 2009. DUSA has not received the installment payments due
under its exclusive Nicomide® patent license agreement with River's Edge since
June 2009. The Company is currently evaluating its options to collect the
amounts due from River's Edge.
DUSA's net loss on a GAAP basis for the third quarter of 2009 was ($0.4)
million, or ($0.02) per common share, compared to a net loss of ($2.8)
million, or ($0.12) per common share, in the third quarter of 2008.
DUSA's non-GAAP net loss for the third quarter of 2009, after adjustments for
stock-based compensation expense, consideration provided to the former Sirius
shareholders, and the non-cash change in fair value of warrants, was ($0.2)
million, or ($0.01) per common share, compared to a net loss of ($1.6)
million, or ($0.07) per common share, in the prior year period. The decrease
in the Company's net loss was primarily the result of the year over year
increase in our PDT revenues and lower operating costs due to the absence of
spending on our Phase IIb acne clinical trial which concluded in 2008.
Please refer to the section entitled "Use of Non-GAAP Financial Measures" and
the accompanying financial table included at the end of this release for a
reconciliation of GAAP to non-GAAP results for the three and nine month
periods ending September 30, 2008 and 2009, respectively.
Year-to-Date 2009 Financial Results:
Total product revenues for the nine month period ended September 30, 2009 were
$21.0 million, down 3% from $21.8 million in comparable prior year period.
PDT revenues totaled $19.8 million, up $3.4 million, or 21% from $16.4 million
for the comparable 2008 period. The increase in PDT revenues was attributable
to a 20% increase in Kerastick® revenues and a 26% increase in BLU-U®
revenues. The Kerastick® revenue improvement was driven by a 13% increase in
our domestic Kerastick® volume and an overall 13% increase in our average
selling price. Kerastick® sales volumes increased to 155,384 in 2009 from
145,256 units sold in 2008. Domestic Kerastick® sales volumes increased by
15,966 units, or 13%, and were partially offset by a 5,838 unit decrease in
our international sales volumes. The BLU-U® revenue increase was driven by a
29% increase in sales volume. There were 198 units sold during in 2009,
representing a 44 unit increase over the prior year total of 154 units.
Non-PDT revenues totaled $1.2 million versus $5.4 million for the comparable
2008 period. Non-PDT revenues were adversely impacted by the absence of
Nicomide® sales in 2009. In response to discussions with the Food and Drug
Administration (FDA) regarding our marketing of certain products considered by
the FDA to be marketed unapproved drugs, the Company stopped shipping
Nicomide® into the wholesale channel in June of 2008.
DUSA's net loss on a GAAP basis for the nine months ended September 30, 2009
was ($2.9) million or ($0.12) per common share, compared to a net loss of
($4.3) million or ($0.18) per common share in 2008.
DUSA's non-GAAP net loss, after adjustments for stock-based compensation
expense, a milestone payment made related to the Sirius acquisition,
consideration provided to the former Sirius shareholders, and the non-cash
change in fair value of warrants, for the nine months ending September 30,
2009 was ($1.9) million, or ($0.08) per common share, in 2009, compared to
($2.5) million, or ($0.10) per common share, in 2008. The decrease in our net
loss was primarily the result of the year over year decrease in our operating
costs due mainly to the absence of spending on our Phase IIb acne clinical
trial which concluded in 2008, and a Prescription Drug User Fee Act (PDUFA)
charge accrued in the prior year period.
As of September 30, 2009, total cash, cash equivalents, and marketable
securities were $15.0 million, compared to $18.9 million at December 31, 2008.
Other Updates:
-- Solid Organ Transplant Recipients Clinical Development.
-- In May 2009, the Company announced the initiation of its Phase II
clinical trial that is examining the safety and efficacy of PDT
for
the treatment of broad area AKs and the prevention of squamous
cell
carcinomas in high risk chronically immunosuppressed solid organ
transplant recipients. All seven clinical sites have been
initiated
and trial enrollment is currently underway.
-- In May 2008, DUSA filed an Orphan Drug Designation application
with
the FDA with respect to the prevention of cancer occurrence in
these
patients. The Company received initial correspondence that the
application was not granted on the basis that the agency believes
that the prevalence of the target population with the disease
state
is greater than 200,000, which is the maximum number of patients
allowed under the Orphan Drug legislation. During the third
quarter
of 2009, DUSA met with the FDA to clarify and explain in more
detail
our rationale for the application and, based on that meeting, the
agency has invited us to submit an amendment to our application
for
further evaluation. DUSA is in the process of drafting the
amendment
and expects to submit it to the FDA later this month.
-- BLU-U® Claims Expansion.
-- In May 2009, the Company filed a 510(k) application with the FDA
to
expand the allowed claims on BLU-U® to include severe acne. The
filing was based on the results of our Phase IIb clinical trial.
We
received a response to our application from the FDA in June 2009.
The agency requested additional information in order to complete
its
review of our application, including supplementary clinical data
in
support of our claims. Based on the FDA's requests and the
anticipated costs of additional clinical trials, the Company has
decided not to pursue the 510(k) application for an expansion of
the
BLU-U® claims at this time.
Revenues Table, Condensed Consolidated Balance Sheets, Condensed Consolidated
Statement of Operations and GAAP to Non-GAAP reconciliation follow:
Revenues for the three month and nine month periods were comprised of the
following:
Three-months ended Nine-months ended
September 30, September 30,
2009 2008 2009 2008
(Unaudited) (Unaudited) (Unaudited) (Unaudited)
PDT Drug & Device Product Revenues
Kerastick(R) Product Revenues:
United States $5,790,000 $4,374,000 $17,096,000 $13,720,000
Canada 162,000 72,000 404,000 449,000
Korea 201,000 186,000 498,000 710,000
Other 91,000 99,000 261,000 289,000
Subtotal Kerastick(R)
Product Revenues 6,244,000 4,731,000 18,259,000 15,168,000
BLU-U(R) Product Revenues:
United States 456,000 376,000 1,577,000 1,198,000
Korea - 50,000 - 50,000
Subtotal BLU-U(R)
Product Revenues 456,000 426,000 1,577,000 1,248,000
Total PDT Drug & Device
Product Revenues 6,700,000 5,157,000 19,836,000 16,416,000
Total Non-PDT Product
Revenues 230,000 569,000 1,198,000 5,352,000
TOTAL PRODUCT REVENUES $6,930,000 $5,726,000 $21,034,000 $21,768,000
DUSA Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
September 30, December 31,
2009 2008
(Unaudited)
--------------------------
ASSETS
CURRENT ASSETS
Cash and cash equivalents $5,016,994 $3,880,673
Marketable securities 10,012,948 15,002,830
Accounts receivable, net 2,519,214 2,367,803
Inventory 2,336,167 2,812,825
Prepaid and other current assets 1,647,408 1,873,801
--------- ---------
TOTAL CURRENT ASSETS 21,532,731 25,937,932
Restricted cash 174,170 173,844
Property, plant and equipment, net 1,721,488 1,937,978
Deferred charges and other assets 68,099 160,700
------ -------
TOTAL ASSETS $23,496,488 $28,210,454
=========== ===========
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable $188,417 $305,734
Accrued compensation 889,230 1,515,912
Other accrued expenses 2,343,822 3,226,571
Deferred revenue 1,045,505 611,602
--------- -------
TOTAL CURRENT LIABILITIES 4,466,974 5,659,819
Deferred revenues 3,061,700 4,157,305
Warrant liability 474,137 436,458
Other liabilities 133,544 244,673
------- -------
TOTAL LIABILITIES 8,136,355 10,498,255
SHAREHOLDERS' EQUITY
Capital stock
Authorized: 100,000,000 shares;
40,000,000 shares designated as
common stock, no par, and
60,000,000 shares issuable in
series or classes; and 40,000
junior Series A preferred shares.
Issued and outstanding: 24,108,908
and 24,089,452 shares of common
stock, no par, at September 30,
2009 and December 31, 2008,
respectively 151,683,399 151,663,943
Additional paid-in capital 8,122,801 7,514,900
Accumulated deficit (144,725,805) (141,850,925)
Accumulated other comprehensive loss 279,738 384,281
TOTAL SHAREHOLDERS' EQUITY 15,360,133 17,712,199
---------- ----------
TOTAL LIABILITIES AND SHAREHOLDERS'
EQUITY $23,496,488 $28,210,454
=========== ===========
DUSA Pharmaceuticals, Inc.
Consolidated Statement of Operations
Three-months ended Nine-months ended
September 30, September 30,
2009 2008 2009 2008
(Unaudited) (Unaudited) (Unaudited) (Unaudited)
Product revenues $6,930,110 $5,726,071 $21,033,920 $21,767,810
Cost of product revenues
and royalties 1,594,692 1,462,028 4,973,782 4,950,039
Gross margin 5,335,418 4,264,043 16,060,138 16,817,771
Operating costs:
Research and development 963,245 1,487,816 3,225,049 5,049,327
Marketing and sales 3,013,351 2,967,431 9,460,766 9,520,865
General and
administrative 1,877,928 1,911,028 6,360,325 6,603,989
Impairment charge for
contingent
consideration - 1,500,000 - 1,500,000
Settlements, net - 650 75,000 (282,775)
Total operating costs 5,854,524 7,866,925 19,121,140 22,391,406
Loss from operations (519,106) (3,602,882) (3,061,002) (5,573,635)
Other income:
Other income, net 79,815 114,260 223,801 538,212
Gain/(loss) on change in
fair value of warrants 24,051 651,767 (37,679) 775,636
Net loss $(415,240) $(2,836,855) $(2,874,880) $(4,259,787)
Basic and diluted net
loss per common share $(0.02) $(0.12) $(0.12) $(0.18)
Weighted average number
of common shares 24,108,908 24,078,610 24,099,786 24,078,546
Use of Non-GAAP Financial Measures
In addition to reporting financial results in accordance with GAAP, DUSA has
provided in the table below non-GAAP financial measures adjusted to exclude
stock-based compensation expense, consideration provided to the former Sirius
shareholders, and the non-cash change in fair value of warrants. The Company
believes that this presentation is useful to help investors better understand
DUSA's financial performance, competitive position and prospects for the
future. Management believes that these non-GAAP financial measures assist in
providing a more complete understanding of the Company's underlying
operational results and trends, and in allowing for a more comparable
presentation of results. Management uses these measures along with their
corresponding GAAP financial measures to help manage the Company's business
and to help evaluate DUSA's performance compared to the marketplace. However,
the presentation of non-GAAP financial measures is not meant to be considered
in isolation or as superior to or as a substitute for financial information
provided in accordance with GAAP. The non-GAAP financial measures used by the
Company may be calculated differently from, and, therefore, may not be
comparable to, similarly titled measures used by other companies.
Investors are encouraged to review the reconciliations of these non-GAAP
financial measures to the comparable GAAP results, contained in the table
below.
Three-months ended Nine-months ended
September 30, September 30,
2009 2008 2009 2008
(Unaudited) (Unaudited) (Unaudited) (Unaudited)
GAAP net loss $(415,240) $(2,836,855) $(2,874,880) $(4,259,787)
Stock-based
compensation (a) 207,178 353,262 631,770 1,042,812
Payment on
acquisition (b) - 1,500,000 - 1,500,000
Consideration to former
Sirius shareholders (c) 5,000 - 310,000 -
Change in fair value
of warrants (d) (24,051) (651,767) 37,679 (775,636)
Non-GAAP adjusted
net loss $(227,113) $(1,635,360) $(1,895,431) $(2,492,611)
Non-GAAP basic and
diluted net loss
per common share $(0.01) $(0.07) $(0.08) $(0.10)
Weighted average
number of common
shares 24,108,908 24,078,610 24,099,786 24,078,546
(a) Stock-based compensation expense resulting from the application
of SFAS 123(R).
(b) Milestone payment related to Sirius Laboratories acquisition.
(c) Payment of $100,000 and accrual of $210,000 related to the release,
consent and the third amendment to the merger agreement between DUSA
and the former Sirius shareholders.
(d) Non-cash gain/loss on change in fair value of warrants.
Conference Call Details and Dial-in Information
In conjunction with this announcement, DUSA will host a conference call
today:
Friday, November 6th - 8:30 a.m. Eastern
If calling from the U.S. or Canada use the following toll-free number:
800.647.4314
Password - DUSA
For international callers use 502.498.8422
Password - DUSA
A recorded replay of the call will be available approximately 15
minutes following the call
U.S. or Canada callers use 877.863.0350
International callers use 858.244.1268
The call will be accessible on our web site approximately six hours following
the call at www.dusapharma.com.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company
focused primarily on the development and marketing of its Levulan® PDT
technology platform, and complementary dermatology products. Levulan® PDT is
currently approved for the treatment of Grade 1 and 2 actinic keratoses of the
face and scalp. DUSA also markets other dermatology products, including
ClindaReach®. DUSA is researching the use of broad area Levulan® PDT to treat
AKs and prevent squamous cell carcinomas in immunosuppressed solid organ
transplant recipients and is supporting research related to oral leukoplakia
in collaboration with the National Institutes of Health. DUSA is based in
Wilmington, Mass. Please visit our web site at www.dusapharma.com.
Except for historical information, this news release contains certain
forward-looking statements that represent our current expectations and beliefs
concerning future events, and involve certain known and unknown risk and
uncertainties. These forward-looking statements relate to Levulan's growth
potential, expectations for filing an amendment to a regulatory application,
and management's beliefs concerning non-GAAP financial measures. These
forward-looking statements are further qualified by important factors that
could cause actual results to differ materially from future results,
performance or achievements expressed or implied by those in the
forward-looking statements made in this release. These factors include,
without limitation, actions by health regulatory authorities, changing
economic conditions, launch of competitive products, the status of our patent
portfolio, reliance on third parties, sufficient funding, and other risks and
uncertainties identified in DUSA's Form 10-K for the year ended December 31,
2008.
SOURCE DUSA Pharmaceuticals, Inc.
Robert F. Doman, President & CEO, +1-978-909-2216, or Richard Christopher, VP
Finance & CFO, +1-978-909-2211, or Chad Rubin, Investor Relations, The Trout
Group LLC, +1-646-378-2947
